Provided by Tiger Trade Technology Pte. Ltd.

Humacyte, Inc.

0.5671
-0.0119-2.06%
Post-market: 0.57000.0029+0.51%19:22 EDT
Volume:2.67M
Turnover:1.52M
Market Cap:157.65M
PE:-1.14
High:0.5800
Open:0.5800
Low:0.5600
Close:0.5790
52wk High:2.55
52wk Low:0.5261
Shares:278.00M
Float Shares:245.00M
Volume Ratio:0.81
T/O Rate:1.09%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4975
EPS(LYR):-0.2582
ROE:-547.87%
ROA:-49.87%
PB:5.04
PE(LYR):-2.20

Loading ...

Humacyte Inc expected to post a loss of 12 cents a share - Earnings Preview

Reuters
·
May 11

Humacyte risks Nasdaq delisting after shares trade below $1 bid price minimum

Reuters
·
May 09

Humacyte Inc expected to post a loss of 12 cents a share - Earnings Preview

Reuters
·
May 08

Humacyte sets first-quarter results webcast and conference call

Reuters
·
May 08

Humacyte to Announce 2026 First Quarter Financial Results and Provide Business Update on May 13, 2026

THOMSON REUTERS
·
May 08

Humacyte (HUMA) Motion to Dismiss Ruling Keeps Key Securities Claims Alive

TIPRANKS
·
May 05

Humacyte (HUMA) Gets a Buy from Barclays

TIPRANKS
·
Apr 29

Humacyte Price Target Maintained With a $3.00/Share by BTIG

Dow Jones
·
Apr 28

Humacyte hosts virtual KOL event on ATEV for dialysis AV access

Reuters
·
Apr 27

Humacyte Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Apr 24

Humacyte Inc - Enters Third Amendment to Distribution Agreement With Fresenius on April 21, 2026 - SEC Filing

THOMSON REUTERS
·
Apr 24

Humacyte Inc - Gains Sole Worldwide Rights to Distribution Product - SEC Filing

THOMSON REUTERS
·
Apr 24

Humacyte Inc - to Pay Fresenius Mid-Single to Low Double Digit Royalties on U.S. Sales - SEC Filing

THOMSON REUTERS
·
Apr 24

Humacyte regains exclusive ex-U.S. Symvess distribution rights from Fresenius Medical Care

Reuters
·
Apr 24

Humacyte Expands Commercial and Business Development Opportunities Through Realignment of Ex-U.S. Rights to Symvess®

THOMSON REUTERS
·
Apr 24

Humacyte Inc - U.S. Distribution Terms for Symvess Remain Unchanged

THOMSON REUTERS
·
Apr 24

Humacyte Inc - Gains Exclusive Ex-U.S. Distribution Rights to Symvess; Fresenius to Receive Low-Single-Digit Royalties on Net Sales

THOMSON REUTERS
·
Apr 24

Humacyte names Jim Mercadante chief commercial officer

Reuters
·
Apr 22

Press Release: Humacyte Appoints Jim Mercadante as Chief Commercial Officer

Dow Jones
·
Apr 22

Humacyte Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Apr 21